$0.35
-0.01 (-1.51%)
Open$0.36
Previous Close$0.35
Day High$0.37
Day Low$0.34
52W High$16.80
52W Low$0.35
Volume—
Avg Volume259.6K
Market Cap3.55M
P/E Ratio—
EPS$-13.92
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+4,722.1% upside
Current
$0.35
$0.35
Target
$16.67
$16.67
$13.69
$16.67 avg
$25.88
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 24.82M | 586.6K | 551.3K |
| Net Income | -214,061,561 | -23,280 | -22,798 |
| Profit Margin | -862.3% | -4.0% | -4.1% |
| EBITDA | -215,113,923 | -32,929 | -31,435 |
| Free Cash Flow | — | -20,426 | -16,844 |
| Rev Growth | +212.6% | +23.9% | +11.9% |
| Debt/Equity | — | 0.35 | 0.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |